ERBB2 and endometrial cancer: Additionally, in the era of molecular-integrated risk profiles for endometrial cancer [45,46], the role of targeted therapies, based on molecular characteristics like HER2 overexpression or mismatch repair deficiency, should be considered alongside standard chemotherapy.